Stemline Therapeutics, Inc. Announces Exercise of Over-Allotment Option
NEW YORK, Jan. 29, 2013 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, today announced the …
See all stories on this topic »